580 related articles for article (PubMed ID: 32185696)
21. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence.
Longo M; Wickes W; Smout M; Harrison S; Cahill S; White JM
Addiction; 2010 Jan; 105(1):146-54. PubMed ID: 19839966
[TBL] [Abstract][Full Text] [Related]
22. A systematic review of risk factors for methamphetamine-associated psychosis.
Arunogiri S; Foulds JA; McKetin R; Lubman DI
Aust N Z J Psychiatry; 2018 Jun; 52(6):514-529. PubMed ID: 29338289
[TBL] [Abstract][Full Text] [Related]
23. Sex Differences in Methamphetamine Use and Dependence in a Thai Treatment Center.
Rungnirundorn T; Verachai V; Gelernter J; Malison RT; Kalayasiri R
J Addict Med; 2017; 11(1):19-27. PubMed ID: 27649265
[TBL] [Abstract][Full Text] [Related]
24. NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines.
National Toxicology Program
NTP CERHR MON; 2005 Jul; (16):vii-III1. PubMed ID: 16130031
[TBL] [Abstract][Full Text] [Related]
25. Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial.
Miles SW; Sheridan J; Russell B; Kydd R; Wheeler A; Walters C; Gamble G; Hardley P; Jensen M; Kuoppasalmi K; Tuomola P; Föhr J; Kuikanmäki O; Vorma H; Salokangas R; Mikkonen A; Kallio M; Kauhanen J; Kiviniemi V; Tiihonen J
Addiction; 2013 Jul; 108(7):1279-86. PubMed ID: 23297867
[TBL] [Abstract][Full Text] [Related]
26. Psychosocial interventions for cannabis use disorder.
Gates PJ; Sabioni P; Copeland J; Le Foll B; Gowing L
Cochrane Database Syst Rev; 2016 May; 2016(5):CD005336. PubMed ID: 27149547
[TBL] [Abstract][Full Text] [Related]
27. LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence.
Ezard N; Dunlop A; Hall M; Ali R; McKetin R; Bruno R; Phung N; Carr A; White J; Clifford B; Liu Z; Shanahan M; Dolan K; Baker AL; Lintzeris N
BMJ Open; 2018 Jul; 8(7):e020723. PubMed ID: 30030312
[TBL] [Abstract][Full Text] [Related]
28. Quite a lot of smoke but very limited fire--the use of methamphetamine in Europe.
Griffiths P; Mravcik V; Lopez D; Klempova D
Drug Alcohol Rev; 2008 May; 27(3):236-42. PubMed ID: 18368604
[TBL] [Abstract][Full Text] [Related]
29. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence.
Shoptaw S; Heinzerling KG; Rotheram-Fuller E; Steward T; Wang J; Swanson AN; De La Garza R; Newton T; Ling W
Drug Alcohol Depend; 2008 Aug; 96(3):222-32. PubMed ID: 18468815
[TBL] [Abstract][Full Text] [Related]
30. Association of clozapine treatment and rate of methamphetamine or amphetamine relapses and abstinence among individuals with concurrent schizophrenia spectrum and amphetamine use disorder: A retrospective cohort study.
Rafizadeh R; Frankow L; Mahmood H; Poonia S; Mathew N; Danilewitz M; Bousman CA; Honer WG; Schütz CG
J Psychopharmacol; 2023 Oct; 37(10):1040-1048. PubMed ID: 37539972
[TBL] [Abstract][Full Text] [Related]
31. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Elliott J; Johnston A; Husereau D; Kelly SE; Eagles C; Charach A; Hsieh SC; Bai Z; Hossain A; Skidmore B; Tsakonas E; Chojecki D; Mamdani M; Wells GA
PLoS One; 2020; 15(10):e0240584. PubMed ID: 33085721
[TBL] [Abstract][Full Text] [Related]
32. Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial.
Morabbi MJ; Razaghi E; Moazen-Zadeh E; Safi-Aghdam H; Zarrindast MR; Vousoghi N; Akhondzadeh S
Int Clin Psychopharmacol; 2018 Mar; 33(2):111-119. PubMed ID: 29064909
[TBL] [Abstract][Full Text] [Related]
33. A study protocol for the N-ICE trial: A randomised double-blind placebo-controlled study of the safety and efficacy of N-acetyl-cysteine (NAC) as a pharmacotherapy for methamphetamine ("ice") dependence.
McKetin R; Dean OM; Turner A; Kelly PJ; Quinn B; Lubman DI; Dietze P; Carter G; Higgs P; Baker AL; Sinclair B; Reid D; Manning V; Te Pas N; Liang W; Thomas T; Bathish R; Kent M; Raftery D; Arunogiri S; Cordaro F; Hill H; Berk M
Trials; 2019 Jun; 20(1):325. PubMed ID: 31164169
[TBL] [Abstract][Full Text] [Related]
34. Drug court treatment for methamphetamine dependence: treatment response and posttreatment outcomes.
Marinelli-Casey P; Gonzales R; Hillhouse M; Ang A; Zweben J; Cohen J; Hora PF; Rawson RA;
J Subst Abuse Treat; 2008 Mar; 34(2):242-8. PubMed ID: 17596903
[TBL] [Abstract][Full Text] [Related]
35. Treatments for methamphetamine abuse: a literature review for the clinician.
Brackins T; Brahm NC; Kissack JC
J Pharm Pract; 2011 Dec; 24(6):541-50. PubMed ID: 22095579
[TBL] [Abstract][Full Text] [Related]
36. Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy.
Ciccarone D
Prim Care; 2011 Mar; 38(1):41-58. PubMed ID: 21356420
[TBL] [Abstract][Full Text] [Related]
37. Clinical management of psychostimulant withdrawal: review of the evidence.
Li MJ; Shoptaw SJ
Addiction; 2023 Apr; 118(4):750-762. PubMed ID: 36401591
[TBL] [Abstract][Full Text] [Related]
38. A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal.
Cruickshank CC; Montebello ME; Dyer KR; Quigley A; Blaszczyk J; Tomkins S; Shand D
Drug Alcohol Rev; 2008 May; 27(3):326-33. PubMed ID: 18368615
[TBL] [Abstract][Full Text] [Related]
39. Prescription psychostimulants for the treatment of amphetamine-type stimulant use disorder: A systematic review and meta-analysis of randomized placebo-controlled trials.
Sharafi H; Bakouni H; McAnulty C; Drouin S; Coronado-Montoya S; Bahremand A; Bach P; Ezard N; Le Foll B; Schütz CG; Siefried KJ; Tardelli VS; Ziegler D; Jutras-Aswad D
Addiction; 2024 Feb; 119(2):211-224. PubMed ID: 37880829
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
